Mr. Rajaram Narayanan

Managing Director

With over 25 years of experience, Mr. Narayanan has a strong track record of leading revenue and profitability growth across multiple industries including pharmaceuticals. He joins from Sanofi India Limited, where he was the Managing Director and Country Chair for India. At Sanofi, he led the strategic reorientation of its India business operations, resulting in accelerated growth in key therapies and significant transformation of Sanofi’s market operations. Before this, he was Chief Marketing Officer at Airtel, India’s leading telecommunications company. Mr. Narayanan started his career at Hindustan Unilever Ltd., where he held various leadership roles in India and other Asian markets for over 18 years, building and managing many iconic consumer brands.

Mr. Narayanan holds a Degree of BE (Hons)-Electrical & Electronics from Birla Institute of Technology and Science, Pilani, and MBA from Indian Institute of Foreign Trade, New Delhi. He has completed the Advanced Management Program from Harvard Business School, USA.

Mr. Sharat Narasapur

Joint Managing Director

Mr. Sharat Narasapur holds a degree in Chemical Engineering from Institute of Chemical Technology – Mumbai, with experience spanning over two decades in Chemical, Agrochemical and Pharmaceutical industry in various roles starting from design and development to managing business operations. He has depth of experience in Techno-commercial operations involving management of large multi-location chemical/ API manufacturing operations, Supply chain management, procurement, planning, manufacturing, QMS/RA, New Product development, Projects & Engineering, Global project /program management and tech transfers. His exposure to product development, process engineering and innovation has resulted in creation of valuable IP. His career spanning over two and a half decades comes with global exposure to customers across big pharma, biotech start-ups and multicultural trans-national work force.

Mr. Narasapur has worked with Company’s like Dr Reddy’s, Gharda Chemicals and his latest assignment was with Aurobindo Pharma as Sr. VP – Operations. He provides leadership to Tech-ops, SCM, QM&RA and R&D for the group.

Mr. Neeraj Bharadwaj

Non Executive Director

Mr. Neeraj Bharadwaj is the Managing Director of Carlyle India Advisors Private Limited, focused on growth capital and buyout opportunities across sectors in India.

Prior to joining Carlyle in 2012, Mr. Bharadwaj was a Managing Director with Accel Partners’ growth investing operation in India. Preceding that he was with Apax Partners for nearly 10 years – he was a Partner in the U.S. and subsequently Managing Director/Country Head for Apax in India, where he led the India operations. Investments he has been involved with include Apollo Hospitals (BSE: AHEL), Jamdat (NASDAQ: JMDT), Widerthan (NASDAQ: WTHN) and others. Previously, Mr. Bharadwaj was an engagement manager at McKinsey & Co.

Mr. Bharadwaj was selected as Board Member of the Indian School of Business (ISB), a Young Global Leader of the World Economic Forum (WEF), Board Member of Olympic Gold Quest (OGQ), Member of the Harvard Business School South Asia Advisory Board, Member of the Wharton Executive Education Board, Member of the Young Presidents’ Organization and previously chaired the FICCI Committee on Private Equity & Venture Capital.

Mr. Bharadwaj serves on the boards of Hexaware, Indegene Nxtra Data Centers, Piramal Pharma, Sequent Scientific, Dailyhunt, CorroHealth and others. Previously, he served on the boards of Delhivery Logistics, Global Health, Metropolis Healthcare, Visionary RCM and others. Mr. Bharadwaj holds an MBA with distinction from Harvard Business School, and graduated summa cum laude with a BS in economics from the Wharton School of the University of Pennsylvania.

Mr. Gregory Andrews

Non Executive Director

Greg is a multi-disciplinary executive with 30 years of commercial experience in the pharmaceutical industry. He is a dynamic business leader who creates a positive impact on the business environment through change and active engagement of both internal and external stakeholders.

Currently Greg is a global animal health consultant with offices in the USA and France. He previously held executive positions within three of the major animal health companies where he gained global experience living and working in Australia, Belgium, France and the USA.

Marketing, communications and management are core disciplines for Greg. He has led many marketing teams in the USA and Europe and most recently was the Global Marketing Director for Virbac. Greg headed global Public Affairs and Policy for Pfizer Animal Health during its IPO transition to Zoetis. He has also held numerous senior management roles including country management for Belgium and the Netherlands and was Vice President for emerging markets in Europe, Africa, Middle East, Russia and CIS.

Greg received a Bachelor of Science (Hons) from Monash University, Australia and Post Graduate Diplomas in both Business Management and International Relations from the University of Tasmania, Australia.

Dr. Fabian Kausche

Non Executive Director

Dr. Kausche is a Chairman of the Board of PetMedix, Cambridge. Dr. Kausche also owns and runs FK Consulting, LLC, Atlanta. He has several decades of experience in the animal and human health industries in both biological and pharmaceutical research and development. He held subsequent positions as Global Head of R&D for Novartis Animal Health, Merial, and Boehringer Ingelheim Animal Health. Worked in the human health space as head of R&D for Novartis Consumer Health. Prior to that, he also successfully led a companion animal sales force for Novartis Animal Health. Dr. Kausche received a veterinary degree from the Hannover Veterinary School. He subsequently completed a Master’s of Science degree at Iowa State University. Following the completion of the M.S. degree, Having completed the Advanced Management Program in 2005, he is also an alumnus of Harvard Business School.

Mr. Milind Sarwate

Independent Director

Milind Sarwate is the Founder & CEO of Increate Value Advisors LLP.

“Increate” means “Uncreated” or “Undiscovered”. Milind set up Increate in 2015 as his second career as an entrepreneur, to help organizations & individuals discover, develop & deliver business & social value. For this, he contributes as required- as Advisor, Mentor, Board Member, or Investor, leveraging his 37-year experience including long stints in Marico & Godrej.

His Advisory roles in Business Value Creation encompass the following

• Helping Private Equity Investors enhance Investee Companies’ value, especially in Consumer / Retail Sectors, across listed and unlisted companies.
• Mentoring promoters and corporate professionals for effective Promotership & Governance
• Capability building and Enhancing effectiveness of Corporate functions, like Finance, HR & Strategy
• Maximizing Value in IPOs / M&As/ Corporate Structuring

His Advisory roles in Social Value Creation cover:

• Guiding Companies in CSR strategy and execution
• Helping Non-Profit Organizations grow and widen their social impact
• Being the middleware between the Social Sector and the Corporate Business sector

His Directorships include 5 listed companies- Mahindra Finance, Hexaware, Glenmark, Metropolis, Matrimony.com- and 3 unlisted companies- OmniActive Health Technologies, Eternis Fine Chemicals and WheelsEMI, all with focus on the audit committee. He also plays Advisory Board role in Bruhat Insights Global, a start up in Artificial Intelligence in HR, and Educo, a School Support NGO.

He invests in promising business/ social enterprises (largely SMEs), by way of venture and angel capital.

He has been awarded ICAI CFO Award (2011), CNBC TV-18 CFO Award (2012) & CFO India Hall of Fame induction (2013).

Milind is a Chartered Accountant, Cost Accountant, Company Secretary and Commerce Graduate. He is a CII-Fulbright Fellow (Carnegie Mellon University, U S A).

Dr. Kamal Sharma

Chairman & Independent Director

Dr. Kamal Sharma has over 48 years of professional experience in executive positions in the Chemical and Pharmaceutical industries and has essayed a wide variety of roles in operations, corporate development and executive management. As the Managing Director of Lupin for a decade between 2003-13, he was instrumental in Lupin achieving leadership position in key markets and businesses, transforming it into one of the largest and fastest growing pharmaceutical companies globally. Previously, he also served as President & Chief Executive of the Life Sciences and speciality group and Member of the Management Board at RPG Enterprises. Mr. Sharma received a Bachelors Degree in Chemical Engineering from IIT Kanpur, a post graduate diploma in Industrial Management from Jamnalal Bajaj Institute of Management Studies and a PhD in Economics from IIT, Mumbai. He has also attended Advanced Management Program (AMP) at Harvard Business School, Boston.

Dr. Kausalya Santhanam

Independent Director

Dr. Kausalya Santhanam is a registered patent agent in the USPTO and India. After eight years of research experience in India and the US, she joined the Intellectual Property Department with CuraGen Corporation, a biopharmaceutical company in USA. She has considerable experience in designing patent strategies. She is currently an IP consultant to Biotechnology and Biopharmaceutical Corporates' both in India and the US.

Dr. Kausalya Santhanam's knowledge and experience in the IP space will be of immense benefit to the Company in the backdrop of increased R&D initiatives.

Dr. Hari Babu Bodepudi

Non Executive Director

Dr. Hari Babu Bodepudi holds a PhD degree in Organic Chemistry from Andhra University and has over 30 years of Industry experience permeating diverse roles in Research, Manufacturing, Quality and operations in both APIs and Oral Solids.

During the last 20 years, he held several leadership roles in technical and commercial operations in Mylan Laboratories, including being the COO of Mylan India, CEO of Mylan India and the Global COO of Mylan. He was responsible for more than 50 Mylan facilities and managing more than 200 APIs and 15000 SKUs of different formulations. At Mylan, he led Mylan’s foray into the ARV business and grew that business to over USD 800mn with global leadership (in volume, value and portfolio spread) and more than 50% market share. He has hands-on experience in global supply chain, regulatory, API R&D, quality and Commercial operations.

Currently he is a Director & CEO at Viyash Life Sciences Private Limited (A Carlyle investee company). He also holds directorship in the following companies:  
1. Symed Labs Limited – Director & CEO  
2. Appcure Labs Private Limited – Director  
3. Vindhya Pharma (India) Private Limited – Director